AAV with EF1a promoter driven CreERT2

This AAV expresses CreERT2 driven by an ubiquitous EF1a promoter.

The 1.2 Kb EF1α promoter is a commonly used, constitutive promoter derived from human elongation factor-1 alpha (EF1α). It is often used in conditions where the other constitutive promoters, such as CMV, have diminished activity or have been silenced.

A mutated form of estrogen ligand-binding domain (ERT2) that binds to synthetic antagonists (such as tamoxifen or its derivative 4-hydroxy-tamoxifen) but not to circulating estrogen, was fused to the Cre recombinase (Cre) to create CreERT2 (also known as “inducible Cre”). When tamoxifen binds to CreERT2, it induces a conformational change of CreERT2, leading to its nuclear translocation, followed by Cre/Lox-mediated recombination.